Veristat Congratulates Origin Biosciences for FDA Approval
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021
Veristat Expands Biometrics Capabilities by Acquiring SQN Clinical
Builds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trials
SOUTHBOROUGH, MA...
Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020
Strengthening its Track Record of Successful Client Regulatory Approval Outcomes
SOUTHBOROUGH, MA – January 14, 2021 – Veristat, a...
Veristat Launches Business Operations in Spain and Names Dr. Montserrat Barceló to Vice...
Leading the Organic and Acquisition Growth of Veristat Operations Throughout Europe
Veristat Named a Top Patient Recruitment Company by PharmaTech Outlook
Delivering A Patient-Centric Approach to Recruitment and Retention for Clinical Trials
SOUTHBOROUGH, MA – December 7, 2020 –Veristat, a...
Veristat Expands Pharmacovigilance and Safety Services with Acquisition of Certus PV
Delivering on Customer Demand for Pharmacovigilance from Clinical Trial Conduct to Post-Marketing Support
Veristat Announces Global Cell and Gene Therapy Center of Excellence
Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to...
Veristat Launches A Flexible Virtual Clinical Trial Solution
Veristat Enhances Patient-Centricity Offering by Delivering Clinical Trials Directly to Patients
SOUTHBOROUGH, MA – September 30, 2020 – ...